Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

0.9419 -0.0481 (-4.86%)
Streaming Delayed Price Updated: 2:51 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
52 Biggest Movers From Friday
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second... 
Via Benzinga
Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why
Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
Via Benzinga
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
- Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - Duration of effect lasted approximately 3 months - No potential distant spread of toxin observed SAN... 
From Dermata Therapeutics
Via AccessWire
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
- Topline results expected in second half of 2022 - Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the... 
From Dermata Therapeutics
Via AccessWire
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -... 
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering
Exposures Product Safety Securities Market
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and... 
From Dermata Therapeutics
Via AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market session. The company's market cap stands at $... 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced... 
Via Benzinga
Dermata Stock Jumps On Positive Psoriasis Candidate Data
Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis. The percentage of treatment... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA 
Via Benzinga
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -... 
From Dermata Therapeutics
Via AccessWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 -... 
From Dermata Therapeutics
Via AccessWire
Topics Initial Public Offering Intellectual Property
Exposures Intellectual Property Product Safety Securities Market
50 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement from management that the company entered into a... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Regencell Bioscience (NASDAQ: 
Via Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share... 
Via Benzinga
Why Are Dermata Therapeutics Shares Trading Higher Today?
Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin... 
From Dermata Therapeutics
Via AccessWire
48 Biggest Movers From Yesterday
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. Trading volume for this security as of 12:30 EST is 3.... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday... 
Via Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Cellect Biotechnology (NASDAQ:APOP) shares rose 68.9% to $9.29 during Friday's pre-market session. The company's market cap stands at $36.4 million.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.